Patient Experience of Early versus Later Intervention in HR Positive Breast Cancer

This segment explores patient centered differences between intervening at molecular emergence of ESR1 mutations with a SERD such as camizestrant and initiating later line therapy after radiographic or clinical progression. Panelists report that early molecular intervention may preserve symptom-free intervals, prolong endocrine sensitivity, and avoid or delay exposures to more toxic systemic regimens, which can translate into better daily functioning and reassurance for patients. Conversely some patients prefer to remain on a tolerated current regimen until objective progression, valuing stability and avoiding the uncertainty of switching therapies based on molecular evidence. Effective alignment of treatment with patient goals requires explicit discussion of expected benefits and uncertainties, anticipated adverse effects, monitoring burden and financial implications. Shared decision making supported by clear communication, routine ctDNA surveillance if chosen, multidisciplinary input, and documentation of patient preferences helps tailor timing of therapy transitions to individual priorities while preserving quality of life and disease control.